Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Novel erythropoiesis stimulating protein: Phase II

Data from an open label dose escalation and pharmacokinetics trial showed that

Read the full 129 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE